While significant chronic progressive deterioration of symptoms independent of or in addition to clinical relapses frequently occurs in MS, such a course of disease is highly atypical and should be considered a red flag in NMOSD [231] (as well as MOG-EM/MOGAD [84]). This evidence concerns the gene MOG and myeloid sarcoma.